Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 13 | 2023 | 164 | 4.370 |
Why?
|
| Rhinitis | 12 | 2023 | 144 | 3.800 |
Why?
|
| Paranasal Sinuses | 5 | 2022 | 63 | 1.640 |
Why?
|
| Nasal Polyps | 6 | 2023 | 54 | 1.350 |
Why?
|
| Immunosuppressive Agents | 2 | 2019 | 120 | 1.170 |
Why?
|
| Paranasal Sinus Neoplasms | 4 | 2022 | 65 | 1.140 |
Why?
|
| Endoscopy | 9 | 2023 | 182 | 0.980 |
Why?
|
| Chronic Disease | 11 | 2023 | 425 | 0.870 |
Why?
|
| Betacoronavirus | 5 | 2020 | 75 | 0.780 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 88 | 0.750 |
Why?
|
| Skull Base Neoplasms | 1 | 2021 | 18 | 0.740 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 92 | 0.740 |
Why?
|
| Papilloma, Inverted | 1 | 2020 | 16 | 0.660 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 190 | 0.610 |
Why?
|
| Nasal Mucosa | 1 | 2018 | 13 | 0.600 |
Why?
|
| Neutrophils | 1 | 2018 | 100 | 0.570 |
Why?
|
| Otolaryngology | 4 | 2021 | 29 | 0.560 |
Why?
|
| Invasive Fungal Infections | 1 | 2017 | 5 | 0.540 |
Why?
|
| Retrospective Studies | 17 | 2023 | 3546 | 0.540 |
Why?
|
| Mucormycosis | 1 | 2017 | 8 | 0.540 |
Why?
|
| Frozen Sections | 1 | 2017 | 14 | 0.540 |
Why?
|
| Aspergillosis | 1 | 2017 | 13 | 0.540 |
Why?
|
| Humans | 34 | 2023 | 27158 | 0.530 |
Why?
|
| Nose Neoplasms | 3 | 2022 | 40 | 0.520 |
Why?
|
| Middle Aged | 15 | 2023 | 9031 | 0.390 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2021 | 35 | 0.360 |
Why?
|
| Adult | 11 | 2023 | 7918 | 0.350 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 28 | 0.330 |
Why?
|
| Simulation Training | 2 | 2020 | 39 | 0.330 |
Why?
|
| Nose | 2 | 2021 | 38 | 0.310 |
Why?
|
| Male | 14 | 2021 | 14821 | 0.290 |
Why?
|
| Female | 14 | 2021 | 15269 | 0.290 |
Why?
|
| Cerebrospinal Fluid Leak | 3 | 2023 | 24 | 0.280 |
Why?
|
| Internship and Residency | 2 | 2021 | 215 | 0.280 |
Why?
|
| Aged | 10 | 2023 | 9084 | 0.250 |
Why?
|
| Tertiary Care Centers | 3 | 2020 | 69 | 0.240 |
Why?
|
| Mometasone Furoate | 2 | 2022 | 8 | 0.240 |
Why?
|
| Skull Base | 2 | 2023 | 35 | 0.240 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 892 | 0.230 |
Why?
|
| Inflammation | 3 | 2023 | 274 | 0.220 |
Why?
|
| Intracranial Hypertension | 1 | 2023 | 14 | 0.210 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 1 | 2023 | 15 | 0.210 |
Why?
|
| Olfaction Disorders | 2 | 2021 | 49 | 0.210 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 129 | 0.190 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2021 | 52 | 0.180 |
Why?
|
| Pandemics | 5 | 2020 | 242 | 0.180 |
Why?
|
| Surgical Flaps | 1 | 2021 | 50 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2021 | 83 | 0.180 |
Why?
|
| Professional Role | 1 | 2021 | 31 | 0.180 |
Why?
|
| Air Pollutants | 1 | 2021 | 11 | 0.180 |
Why?
|
| Air Pollution | 1 | 2021 | 14 | 0.180 |
Why?
|
| Treatment Outcome | 4 | 2023 | 3525 | 0.180 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 61 | 0.180 |
Why?
|
| Natural Killer T-Cells | 1 | 2020 | 3 | 0.180 |
Why?
|
| Child | 2 | 2022 | 1260 | 0.180 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2020 | 4 | 0.180 |
Why?
|
| Melanoma | 1 | 2021 | 58 | 0.180 |
Why?
|
| Hemostatic Techniques | 1 | 2020 | 8 | 0.170 |
Why?
|
| Nasal Surgical Procedures | 2 | 2017 | 10 | 0.170 |
Why?
|
| Nasopharynx | 1 | 2020 | 5 | 0.170 |
Why?
|
| Epistaxis | 1 | 2020 | 9 | 0.170 |
Why?
|
| Personnel, Hospital | 1 | 2020 | 15 | 0.170 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2020 | 8 | 0.170 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2020 | 11 | 0.170 |
Why?
|
| Airway Management | 1 | 2020 | 15 | 0.170 |
Why?
|
| Urban Health Services | 1 | 2020 | 13 | 0.170 |
Why?
|
| Smell | 1 | 2020 | 17 | 0.170 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 305 | 0.170 |
Why?
|
| Tracheostomy | 1 | 2020 | 24 | 0.170 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 2020 | 7 | 0.170 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 79 | 0.170 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 23 | 0.170 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2020 | 5 | 0.170 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 29 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 667 | 0.170 |
Why?
|
| Sella Turcica | 1 | 2019 | 4 | 0.160 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 146 | 0.160 |
Why?
|
| Surgeons | 1 | 2021 | 88 | 0.160 |
Why?
|
| Surgical Wound | 1 | 2019 | 10 | 0.160 |
Why?
|
| Preoperative Care | 1 | 2020 | 119 | 0.160 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2019 | 30 | 0.160 |
Why?
|
| Carcinoma | 1 | 2020 | 68 | 0.160 |
Why?
|
| Disease Management | 1 | 2020 | 104 | 0.160 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 63 | 0.160 |
Why?
|
| Maxillary Diseases | 1 | 2018 | 4 | 0.150 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 347 | 0.150 |
Why?
|
| Fibrosis | 1 | 2018 | 31 | 0.150 |
Why?
|
| Wound Healing | 1 | 2019 | 154 | 0.150 |
Why?
|
| Phenotype | 1 | 2019 | 312 | 0.150 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 122 | 0.150 |
Why?
|
| Telemedicine | 1 | 2020 | 98 | 0.150 |
Why?
|
| Clinical Competence | 1 | 2020 | 210 | 0.140 |
Why?
|
| Olfactory Nerve | 1 | 2017 | 2 | 0.140 |
Why?
|
| Olfactory Receptor Neurons | 1 | 2017 | 2 | 0.140 |
Why?
|
| Frontal Sinus | 1 | 2017 | 13 | 0.140 |
Why?
|
| Young Adult | 3 | 2020 | 2026 | 0.140 |
Why?
|
| Mucor | 1 | 2017 | 5 | 0.140 |
Why?
|
| Aspergillus | 1 | 2017 | 7 | 0.140 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 46 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 218 | 0.130 |
Why?
|
| Acute Disease | 1 | 2017 | 177 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 4831 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 485 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2021 | 928 | 0.120 |
Why?
|
| Decision Making | 1 | 2017 | 220 | 0.120 |
Why?
|
| Prognosis | 3 | 2021 | 804 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2021 | 1783 | 0.090 |
Why?
|
| Immunotherapy | 2 | 2021 | 59 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2021 | 261 | 0.090 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 368 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2021 | 350 | 0.080 |
Why?
|
| Survival Rate | 2 | 2020 | 344 | 0.080 |
Why?
|
| Chicago | 2 | 2020 | 948 | 0.070 |
Why?
|
| Risk Factors | 2 | 2021 | 2334 | 0.060 |
Why?
|
| Adolescent | 2 | 2020 | 2179 | 0.050 |
Why?
|
| Encephalocele | 1 | 2023 | 26 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 36 | 0.050 |
Why?
|
| Eosinophils | 1 | 2022 | 42 | 0.050 |
Why?
|
| Nasal Lavage | 1 | 2021 | 4 | 0.050 |
Why?
|
| Pituitary-Adrenal System | 1 | 2021 | 13 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2023 | 589 | 0.050 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2021 | 23 | 0.050 |
Why?
|
| Tourette Syndrome | 1 | 2021 | 11 | 0.050 |
Why?
|
| Hydrocortisone | 1 | 2021 | 39 | 0.050 |
Why?
|
| Taste Disorders | 1 | 2021 | 4 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 30 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2021 | 18 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 177 | 0.040 |
Why?
|
| Particulate Matter | 1 | 2021 | 18 | 0.040 |
Why?
|
| Observer Variation | 1 | 2021 | 97 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 41 | 0.040 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 4 | 0.040 |
Why?
|
| Education, Nursing, Continuing | 1 | 2020 | 9 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 350 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 20 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 397 | 0.040 |
Why?
|
| Inservice Training | 1 | 2020 | 26 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 37 | 0.040 |
Why?
|
| Nasal Cavity | 1 | 2020 | 33 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2020 | 13 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 36 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2020 | 58 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 32 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 76 | 0.040 |
Why?
|
| Genomics | 1 | 2020 | 64 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2020 | 32 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 55 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 202 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 197 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 303 | 0.040 |
Why?
|
| Mass Screening | 1 | 2020 | 173 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 458 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 673 | 0.040 |
Why?
|
| Eosinophilia | 1 | 2018 | 39 | 0.040 |
Why?
|
| Smoking | 1 | 2019 | 183 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 320 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 775 | 0.030 |
Why?
|
| Time Factors | 1 | 2021 | 1438 | 0.030 |
Why?
|
| Cadaver | 1 | 2017 | 373 | 0.030 |
Why?
|
| United States | 1 | 2020 | 2066 | 0.030 |
Why?
|
Papagiannopoulos's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(160)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(23)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_